Recently, the American Diabetes Association (ADA) 68th Annual Meeting announced the largest diabetes treatment study to date: the ADVANCE study; and published the results of the study in conjunction with the prestigious New England Journal of Medicine. The results of this study show that intensive glycemic control with a treatment goal of lowering glycosylated hemoglobin values below 6.5% in patients with type 2 diabetes with cardiovascular risk factors can further reduce various vascular complications. After 5 years of observation, the study confirmed that an intensive glucose-lowering regimen based on gliclazide extended-release tablets (Damacell extended-release tablets) achieved safe glucose-lowering targets and significantly reduced the risk of major macrovascular and microvascular composite endpoints by 10%, including cardiovascular death, diabetic nephropathy events and other most common diabetic complications, with a 21% reduction in nephropathy and a 30% reduction in proteinuria, which were also It is also a major predictor of reduced cardiovascular mortality. The ADVANCE study was conducted by the prestigious George International Health Research Centre in Australia and involved more than 10,000 patients with type 2 diabetes in more than 20 countries worldwide. The new dosage form has the advantage of being able to safely and effectively lower glucose once a day for 24 hours, and also has vascular protective properties such as antioxidants to reduce atherosclerosis, making it an ideal oral sulfonylurea glucose-lowering drug recommended by the guidelines. It is noteworthy that one-third of the patients in this study were from China, which will undoubtedly provide more sufficient and strong evidence for the treatment strategy of diabetes in China. The latest guidelines for the prevention and treatment of type 2 diabetes in China issued by the Chinese Medical Association’s Division of Diabetes clearly state that the goal of glycosylated hemoglobin control for diabetic patients is less than 6.5%, which is the target blood glucose of the AD-VANCE study.